Mepolizumab biosimilar - Bio-Thera Solutions

Alternative Names: BAT-2606

Latest Information Update: 05 Sep 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bio-Thera Solutions
Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Interleukin 5 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 Jun 2023 Bio-Thera Solutions completes a phase-I trial in Autoimmune disorders (In volunteers) in China (SC) (NCT05576454)
14 Oct 2022 Bio-Thera Solutions plans to file BLA/MAA with NMPA, FDA, EMA and other regulatory bodies around the world
14 Oct 2022 Bio-Thera Solutions plans a phase III trial

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com